Woolsey SJ et al. |
Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26399557
|
de Graan AJ et al. |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. |
2015 |
Br J Clin Pharmacol |
pmid:26119961
|
Hukkanen J et al. |
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. |
2015 |
Br J Clin Pharmacol |
pmid:26095142
|
Mannheimer B et al. |
No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. |
2015 |
PLoS ONE |
pmid:25835492
|
Ngaimisi E et al. |
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. |
2014 |
J. Antimicrob. Chemother. |
pmid:25096076
|
Huang MQ et al. |
Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. |
2014 |
Biomed. Chromatogr. |
pmid:24861746
|
Dutreix C et al. |
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. |
2014 |
Eur. J. Clin. Pharmacol. |
pmid:24839948
|
Kasichayanula S et al. |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. |
2014 |
Br J Clin Pharmacol |
pmid:24837659
|
Nylén H et al. |
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. |
2014 |
Basic Clin. Pharmacol. Toxicol. |
pmid:24655660
|
Li K et al. |
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. |
2014 |
Drug Metab. Dispos. |
pmid:24595680
|
Ikegami T et al. |
Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. |
2014 |
Biochem. Biophys. Res. Commun. |
pmid:24525121
|
Suzuki Y et al. |
Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. |
2014 |
Drug Metab. Dispos. |
pmid:24135442
|
van de Merbel NC and de Vries R |
Aging of biological matrices and its effect on bioanalytical method performance. |
2013 |
Bioanalysis |
pmid:24066624
|
Xu Y et al. |
LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. |
2013 |
J Pharm Biomed Anal |
pmid:23948760
|
DeGorter MK et al. |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. |
2013 |
Circ Cardiovasc Genet |
pmid:23876492
|
Suzuki Y et al. |
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. |
2013 |
J. Lipid Res. |
pmid:23833241
|
Shin KH et al. |
Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. |
2013 |
Clin. Pharmacol. Ther. |
pmid:23784264
|
Björkhem-Bergman L et al. |
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. |
2013 |
Drug Metab. Dispos. |
pmid:23674608
|
Higashi T et al. |
LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. |
2013 |
Chem. Pharm. Bull. |
pmid:23449202
|
Björkhem-Bergman L et al. |
Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. |
2013 |
Drug Metab. Dispos. |
pmid:23386704
|